Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through artificial-intelligence-powered drug development. The two companies will establish a new AI co-innovation lab with a commitment to invest more than $1 billion over five years, Nvidia announced at the 2026 J.P. Morgan Healthcare Conference in San Francisco. “This co-innovation lab is dedicated to achieving accelerated, closed-loop discovery and the creation of AI models to improve clinical development,” Kimberly Powell, vice president of healthcare at Nvidia, said in a press briefing.

Full report : Nvidia and Eli Lilly plan to invest $1B over five years in a new Silicon Valley-based AI drug laboratory, aiming to boost the pharmaceutical industry’s AI use.